REMINDER: Our user survey closes on Friday, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8 (OPD) Sopheon plc

8 Nov 2023 07:00

RNS Number : 7076S
Sopheon PLC
08 November 2023
 

FORM 8 (OPD)

 

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER

Rules 8.1 and 8.2 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

Sopheon plc

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

N/A

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Sopheon plc

(d) Is the discloser the offeror or the offeree?

OFFEREE

(e) Date position held:

The latest practicable date prior to the disclosure

07 November 2023

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

 

2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

 

Class of relevant security:

 

20p Ordinary

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

Nil

0.00

Nil

0.00

(2) Cash-settled derivatives:

 

Nil

0.00

Nil

0.00

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

Nil

0.00

Nil

0.00

 

TOTAL:

Nil

0.00

Nil

0.00

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

(b) Rights to subscribe for new securities

 

Class of relevant security in relation to which subscription right exists:

None

Details, including nature of the rights concerned and relevant percentages:

N/A

 

 

3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

Details of any interests, short positions and rights to subscribe (including directors' and other employee options) of any person acting in concert with the party to the offer making the disclosure:

 

 

A) Holdings of ordinary shares by directors of Sopheon plc and their close relatives:

 

Name

No. Ordinary Shares Held

% of total issued share capital carrying voting rights

Barry Mence*

1,899,458

17.84%

Arif Karimjee**

73,500

0.69%

Daniel Metzger

5,000

0.05%

Andrew Michuda

67,620

0.64%

Stuart Silcock***

282,990

2.66%

Greg Coticchia

8,600

0.08%

Barnaby Kent

3,500

0.03%

 

*includes 265,825 ordinary shares held by his wife, Maria Mence

** includes 26,600 ordinary shares held by his wife, Fiona Karimjee

*** includes 16,625 ordinary shares held by his wife, Christine Silcock

 

B) The directors of the Company have the following rights to subscribe for the following relevant Sopheon plc securities under the share options plans:

 

Name

Date of Grant

Vesting period

Latest Exercisable Date

Exercise price (£)

No. of options outstanding

Arif Karimjee

15 February 2017

15 February 2017 to 14 February 2020

15 February 2027

4.68

11,650

Arif Karimjee

11 February 2018

11 February 2018 to 10 February 2021

11 February 2028

5.65

15,000

Arif Karimjee

4 July 2018

4 July 2018 to 3 July 2021

3 July 2028

9.00

15,000

Arif Karimjee

10 July 2020

10 July 2020 to 9 July 2023

10 July 2030

7.75

8,000

Arif Karimjee

14 May 2021

14 May 2021 to 13 May 2024

14 May 2031

9.00

43,350

Andrew Michuda

15 February 2017

15 February 2017 to 14 February 2020

15 February 2027

4.68

25,000

Andrew Michuda

11 February 2018

11 February 2018 to 10 February 2021

11 February 2028

5.65

50,000

Andrew Michuda

4 July 2018

4 July 2018 to 3 July 2021

3 July 2028

9.00

50,000

Andrew Michuda

10 July 2020

10 July 2020 to 9 July 2023

10 July 2030

7.75

30,000

Andrew Michuda

14 May 2021

14 May 2021 to 13 May 2024

14 May 2031

9.00

165,000

Greg Coticchia

19 October 2020

19 October 2020 to 18 October 2023

19 October 2030

7.85

20,000

Greg Coticchia

14 May 2021

14 May 2021 to 13 May 2024

14 May 2031

8.45

80,000

 

 

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

None

 

 

(c) Attachments

 

Are any Supplemental Forms attached?

 

Supplemental Form 8 (Open Positions)

NO

Supplemental Form 8 (SBL)

NO

 

 

Date of disclosure:

08 November 2023

Contact name:

Arif Karimjee, Chief Financial Officer

Telephone number:

+44 1276 919 560 

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FEEBDLLBXFLFFBD
Date   Source Headline
24th Jul 20199:05 amRNSSecond Price Monitoring Extn
24th Jul 20199:00 amRNSPrice Monitoring Extension
24th Jul 20197:00 amRNSTrading Update
13th Jun 20191:06 pmRNSResult of AGM
13th Jun 20197:00 amRNSAccolade 12.3
13th Jun 20197:00 amRNSAGM Statement
11th Jun 20191:32 pmRNSIssue of Equity
15th May 20197:00 amRNSSopheon Expands Customer Foothold in Asia
13th May 20199:14 amRNSIssue of Equity
28th Mar 20197:00 amRNSSopheon and National Foods Limited Partnership
21st Mar 20197:00 amRNSFinal Results
5th Feb 20197:00 amRNSIssue of Equity
29th Jan 20197:00 amRNSTrading Update
24th Jan 20194:41 pmRNSSecond Price Monitoring Extn
24th Jan 20194:35 pmRNSPrice Monitoring Extension
17th Jan 20197:00 amRNSAccolade Release 12.2
11th Jan 20197:00 amRNSTrading Update
8th Jan 20197:00 amRNSSopheon Partners with The Hershey Company
18th Dec 20182:53 pmRNSIssue of Equity
16th Nov 201812:54 pmRNSIssue of Equity
31st Oct 20185:18 pmRNSIssue of Equity
23rd Oct 20187:00 amRNSSopheon Awarded The Nature's Bounty Co. Business
8th Oct 20189:05 amRNSSecond Price Monitoring Extn
8th Oct 20189:00 amRNSPrice Monitoring Extension
8th Oct 20187:00 amRNSTrading Update
10th Sep 20187:00 amRNSDoosan Bobcat Awards Sopheon Innovation Contract
7th Sep 20185:48 pmRNSIssue of Equity
29th Aug 20183:54 pmRNSIssue of Equity & Holdings in Company
28th Aug 20187:00 amRNSAccolade Enterprise Innovation Management
23rd Aug 20187:00 amRNSHalf Yearly Report
19th Jul 201811:05 amRNSSecond Price Monitoring Extn
19th Jul 201811:00 amRNSPrice Monitoring Extension
19th Jul 20187:00 amRNSTrading Update
5th Jul 20189:40 amRNSGrant of Options / PDMR Dealing
3rd Jul 20189:24 amRNSIssue of Equity
13th Jun 20182:37 pmRNSIssue of Equity
7th Jun 201812:09 pmRNSResult of AGM
7th Jun 20187:00 amRNSAGM Statement
31st May 20182:56 pmRNSIssue of Equity
17th May 20188:01 amRNSResult of Secondary Placing
16th May 20183:05 pmRNSProposed Secondary Placing
15th May 20187:00 amRNSIssue of Equity
27th Apr 20183:59 pmRNSIssue of Equity
29th Mar 20187:00 amRNSAccolade Release 12.0
23rd Mar 20183:56 pmRNSIssue of Equity
23rd Mar 20187:00 amRNSIssue of Equity
22nd Mar 20187:00 amRNSFinal Results
20th Feb 20187:00 amRNSSopheon named in Annual Reader's Choice List
12th Feb 20189:24 amRNSGrant of Options / PDMR dealing
5th Feb 20183:35 pmRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.